Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2041

Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.

Patents
2,000

Quick answer

2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10934547

    Use of trinucleotide repeat RNAs to treat cancer

    Northwestern University · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10934545

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10935554

    Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10934274

    Quinoline derivatives as TAM RTK inhibitors

    Lead Discovery Center GmbH · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10934305

    SHMT inhibitors

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10934550

    Immunotherapy of cancer

    Phio Pharmaceuticals Corp. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10934349

    Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that is an anti-GDF8 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10934363

    Chimeric antigen receptors based on single domain antibodies and methods of use thereof

    LEGEND BIOTECH USA INC. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10933130

    Vaccines with interleukin-33 as an adjuvant

    Inovio Pharmaceuticals, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10934302

    SHP2 phosphatase inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10933094

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10934306

    Hepatitis B antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10934534

    Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10934360

    Human monoclonal antibodies against EPHA4 and their use

    The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10933022

    Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same

    Oramed Ltd. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10934527

    Generation of lineage-restricted progenitor cells from differentiated cells

    The Regents of the University of California · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10934337

    Anti-BCMA chimeric antigen receptors

    Cartesian Therapeutics, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10934334

    Peptides for angiogenic therapy

    The Regents of the University of California · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10934332

    Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment

    The Regents of the University of California · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10934264

    Amyloid targeting agents and methods of using the same

    The Regents of the University of California · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10933136

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10934260

    Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide

    MEREO BIOPHARMA 1 LIMITED · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10933137

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10934299

    Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors

    Valo Early Discovery, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10933126

    Clostridium difficile immunogenic compositions and methods of use

    The Board of Regents of the University of Oklahoma · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10934270

    Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity

    Northwestern University · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10933086

    Composition for preventing, alleviating, or treating arthritis or osteoporosis, containing neoagarooligosaccharide

    DYNEBIO INC. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10933078

    Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling

    The Board of Regents of the University of Texas System · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10933076

    Crocin-sorafenib combination therapy for liver cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10933071

    Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10933066

    Methods and compositions for treatment of Zika virus infection

    BioCryst Pharmaceuticals, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10933042

    Intravenous baclofen formulations and treatment methods

    Regents of the University of Minnesota · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10933056

    3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor

    MSD R&D (China) Co. Ltd. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10932484

    Inhibitory activity of acetogenins against Listeria monocytogenes

    INSTITUTO TECNOLÓGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10933081

    Myostatin iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. CA 3152006

    TROPOELASTINE DESTINEE A ETRE UTILISEE DANS LE TRAITEMENT DE LA CICATRISATION DE L'ACNE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Thu Mar 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10939673

    Method of using mouse having a humanized cluster of differentiation 47 gene

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10940142

    Inhibition of crystal growth of roflumilast

    Arcutis, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10940160

    Biomarkers for predicting responsiveness to decitabine therapy

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10940153

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10940168

    Method of treating Bruch's membrane hypofunction disease

    Altregen Co., Ltd. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10941128

    Thymoquinone derivatives for treatment of cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10940133

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    Jazz Pharmaceuticals Ireland Limited · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10940208

    Nanoassembled complexes of nucleic acids, avidin and biotinylated compounds for use as drug carriers

    UVERA SRL · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10940214

    Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord

    The Regents of the University of California · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10941135

    Nrf2 activating compounds and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10941200

    TREM2 cleavage modulators and uses thereof

    Ludwig-Maximilians-Universitat Munchen · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10940241

    Formation of stable cartilage

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2041?

2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.